For laboratory research use only. This page summarizes public scientific literature. It is not medical advice and does not describe or endorse human, clinical, or veterinary use.
Chemistry & identity
| CAS Number | 2023788-19-2 |
|---|---|
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813 g/mol |
| Residue Count | 39 |
| PubChem CID | 156588324 |
Peptide sequence
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS
Research context
Sequence X = 2-aminoisobutyric acid (Aib) at positions 2 and 13, per DrugBank DB15171. PubChem-computed molecular weight is reported to 4 significant figures (4813 g/mol); DrugBank lists 4810.52 Da.
Selected research references
Published peer-reviewed literature on Tirzepatide. Provided for research-context purposes only; CC Peptides does not make claims about outcomes in humans.
- Tirzepatide for Obesity Treatment and Diabetes Prevention
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Tirzepatide for laboratory research
CC Peptides supplies Tirzepatide as a lyophilized reference material with a third-party COA. Ships from California.
View product page →